Objectif Governments in Europe (and beyond) have begun to express grave concern about a number of acute, transnational health threats endangering their citizens and economies. Whether it is the spectre of a future pandemic, the threat of a bioterrorist attack, or the continuing burden of infectious diseases in many developing countries - strengthening the protection against transnational public health threats is increasingly viewed as an urgent matter of international politics. Ongoing efforts by the European Union to develop its own health security strategy will require the formation of effective and sustainable partnerships with numerous stakeholders, including the scientific, medical, and public health communities, as well as private industry – especially in the form of pharmaceutical companies. The latter are particularly crucial actors because of the prominent role that pharmaceutical therapies like vaccines, antivirals, antibiotics, etc. play in strengthening health security. Cooperation with the pharmaceutical industry is therefore necessary to ensure that the required drugs are available in sufficient quantities, in the places where they are needed, and at the right time. Yet very little – if anything – is actually known about the role of pharmaceutical companies in the formulation and implementation of health security policy. This crucial area not only remains under-researcher; it is, in fact, almost entirely un-researched. The core research challenge this project takes up, therefore, is to conduct the first systematic study of the role of pharmaceutical businesses in health security. The aim of the project is both to improve our understanding of the role that pharmaceutical companies play in shaping contemporary health security policy, and to explore how the emerging (but also politically sensitive) partnerships with pharmaceutical companies can be responsibly managed in the years ahead. Champ scientifique medical and health scienceshealth sciencespublic healthepidemiologyepidemics preventionmedical and health scienceshealth sciencesinfectious diseasesmedical and health scienceshealth sciencespublic healthepidemiologypandemicsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantivirals Programme(s) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Thème(s) ERC-SG-SH2 - ERC Starting Grant - Institutions, values, beliefs and behaviour Appel à propositions ERC-2012-StG_20111124 Voir d’autres projets de cet appel Régime de financement ERC-SG - ERC Starting Grant Institution d’accueil THE UNIVERSITY OF SUSSEX Contribution de l’UE € 1 197 693,80 Adresse SUSSEX HOUSE FALMER BN1 9RH Brighton Royaume-Uni Voir sur la carte Région South East (England) Surrey, East and West Sussex Brighton and Hove Type d’activité Higher or Secondary Education Establishments Chercheur principal Stefan Elbe (Prof.) Contact administratif David Rose (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Bénéficiaires (1) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire THE UNIVERSITY OF SUSSEX Royaume-Uni Contribution de l’UE € 1 197 693,80 Adresse SUSSEX HOUSE FALMER BN1 9RH Brighton Voir sur la carte Région South East (England) Surrey, East and West Sussex Brighton and Hove Type d’activité Higher or Secondary Education Establishments Chercheur principal Stefan Elbe (Prof.) Contact administratif David Rose (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée